Skip to main content
. 2018 Jan 8;75(3):320–327. doi: 10.1001/jamaneurol.2017.4011

Figure 2. Drug Survival and Reasons for Therapy Discontinuation for Treatment Groups.

Figure 2.

Kaplan-Meier curve for drug survival (A) and cumulative incidence reasons for therapy discontinuation for rituximab (RTX) (B), interferon beta and glatiramer acetate (INJ) (C), dimethyl fumarate (DMF) (D), and natalizumab (NTZ) (E). The most frequent reason to stop INJ and DMF was disease breakthrough; the most common reason to stop NTZ was John Cunningham virus (JCV) titers. Owing to the smaller size of the fingolimod (FGL) group (n = 17) reasons for therapy discontinuation are not presented.